Celgene Corp (NASDAQ:CELG)

95.61
Delayed Data
As of Feb 23
 +1.83 / +1.95%
Today’s Change
88.32
Today|||52-Week Range
147.17
-8.38%
Year-to-Date
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
Feb 22 / Zacks.com - Paid Partner Content
Celgene Reports Positive Data on Dermatology Drug Otezla
Feb 19 / Zacks.com - Paid Partner Content
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
Feb 20 / Zacks.com - Paid Partner Content
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Feb 16 / Zacks.com - Paid Partner Content
David Rolfe Axes TreeHouse Foods, Exxon Mobil in 4th Quarter
Feb 19 / GuruFocus News - Paid Partner Content
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
Feb 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close93.78
Today’s open94.54
Day’s range93.94 - 95.66
Volume4,031,211
Average volume (3 months)8,153,147
Market cap$70.5B
Data as of 4:00pm ET, 02/23/2018

Growth & Valuation

Earnings growth (last year)+46.18%
Earnings growth (this year)+14.02%
Earnings growth (next 5 years)+18.50%
Revenue growth (last year)+17.40%
P/E ratio26.3
Price/Sales6.58
Price/Book10.29

Competitors

 Today’s
change
Today’s
% change
BMYBristol-Myers Squibb+2.01+3.05%
GSKGlaxoSmithKline+0.27+0.74%
ABBVAbbVie+1.19+1.01%
SNYSanofi+0.28+0.70%
Data as of 4:02pm ET, 02/23/2018

Financials

Next reporting dateApril 26, 2018
EPS forecast (this quarter)$1.95
Annual revenue (last year)$12.8B
Annual profit (last year)$2.9B
Net profit margin22.93%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Mark J. Alles
President &
Chief Operating Officer
Scott Andrew Smith
Corporate headquarters
Summit, New Jersey

Forecasts